Bullish & Foolish
Full ATOS fundamentals All 466 on the Survival Watch

ATOSATOSSA THERAPEUTICS, INC.

Is Atossa Therapeutics struggling financially?

Yes, by its own account. Atossa Therapeutics told the SEC on 8 May 2026, in Form 10-Q, that there is substantial doubt about its ability to continue as a going concern.

Going concern disclosed May 2026

30/100

Fragile

Sector
Biotech/Pharma
Market cap
$25.3M
Source filing
10-Q 8 May 2026
Balance sheet
30 Jun 2026

Cash runway

  • 8months

    If the burn speeds up

    Empty by Mar 2027

  • 13months

    If it eases off

    Empty by Jul 2027

Both rows are the same reported burn flexed 15% either way, and neither assumes the company raises a cent.

Out of cashTwo years or more

The runway math

Cash and short-term investments

$26.1M

÷

Cash burned over the last 12 months

$29.8M

What Atossa Therapeutics told the SEC

…an ongoing source of revenue sufficient to cover its operating costs and allow it to continue as a going concern. The ability of the Company to continue as a going concern is dependent on the Company obtaining adequate capital to fund operating losses until it becomes profitable. These conditions raise substantial doubt as to the Company's ability to continue as a going concern. The accompanying Condensed Consolidated Financial Statements do not include any adjustments relating to the…

ATOSSA THERAPEUTICS, INC., Form 10-Q, filed 8 May 2026.

Read the filing on SEC.gov

What this means

  • Not a bankruptcy filing, and not a prediction.
  • It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
  • The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.

What else the numbers show

  • Cash burn is narrowing It is spending 26% less cash per year than it was, so the runway above is lengthening rather than shortening.

Other Biotech/Pharma companies that filed the doubt